MAVIRENA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 294,073 | 341,213 | 403,761 | 351,294 | 291,840 | 292,296 | 385,933 | 433,379 |
| Profit before tax | 22,232 | 30,986 | 88,319 | -43,673 | -69,192 | -20,786 | -21,568 | -26,686 |
| Net profit | 18,897 | 26,338 | 75,071 | -43,673 | -69,192 | -20,786 | -21,568 | -26,686 |
| Equity | 68,615 | 94,953 | 170,024 | 126,351 | 57,159 | 36,373 | 14,805 | -11,881 |
| Liabilities | 104,057 | 149,872 | 165,593 | 88,119 | 86,392 | 81,020 | 178,789 | 138,205 |
| Non-current assets | 79,380 | 139,098 | 154,256 | 135,821 | 112,187 | 102,907 | 150,393 | 134,903 |
| Current assets | 93,292 | 105,727 | 181,361 | 78,649 | 31,364 | 14,486 | 43,201 | -8,579 |
| Total assets | 172,672 | 244,825 | 335,617 | 214,470 | 143,551 | 117,393 | 193,594 | 126,324 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 22,746 | 23,430 | 44,806 |
| Social insurance contributions | - | - | - | - | - | 14,904 | 20,701 | 28,112 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -7.5% | +16.0% | +18.3% | -13.0% | -16.9% | +0.2% | +32.0% | +12.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 10.9% | 10.8% | 22.4% | -20.4% | -48.2% | -17.7% | -11.1% | -21.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 27.5% | 27.7% | 44.2% | -34.6% | -121.1% | -57.1% | -145.7% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 6.4% | 7.7% | 18.6% | -12.4% | -23.7% | -7.1% | -5.6% | -6.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.6% | 9.1% | 21.9% | -12.4% | -23.7% | -7.1% | -5.6% | -6.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.5 | 1.6 | 1.0 | 0.7 | 1.5 | 2.2 | 12.1 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 40,101 | 43,559 | 58,375 | 57,747 | 58,368 | 59,450 | 60,145 | 55,325 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MAVIRENA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-09-16 | 2026-09-16 | 1970.48 |
| 2026-07-26 | 2026-07-26 | 11.10 |
| 2026-07-23 | 2026-07-25 | 15.91 |
| 2026-07-19 | 2026-07-22 | 11.10 |
| 2026-07-16 | 2026-07-17 | 11.10 |
| 2026-05-18 | 2026-05-25 | 22.09 |
| 2026-05-17 | 2026-05-17 | 2297.20 |
| 2026-05-03 | 2026-05-14 | 6.07 |
| 2026-04-27 | 2026-04-29 | 6.07 |
| 2026-04-26 | 2026-04-26 | 3.24 |
| 2026-04-24 | 2026-04-25 | 6.07 |
| 2026-04-20 | 2026-04-23 | 3.24 |
| 2026-03-27 | 2026-03-27 | 2192.65 |
| 2026-03-17 | 2026-03-22 | 2192.65 |
| 2026-01-16 | 2026-01-27 | 25.46 |
| 2025-11-18 | 2025-11-27 | 56.59 |
| 2025-10-16 | 2025-11-02 | 2.02 |
| 2025-09-16 | 2025-10-14 | 1.93 |
| 2025-09-07 | 2025-09-09 | 1.97 |
| 2025-08-31 | 2025-09-03 | 1.97 |
| 2025-08-19 | 2025-08-29 | 1.97 |
| 2025-07-16 | 2025-08-11 | 1.97 |
| 2025-06-17 | 2025-07-10 | 1.97 |
| 2025-06-08 | 2025-06-09 | 1.97 |
| 2025-05-16 | 2025-06-04 | 1.97 |
| 2025-05-04 | 2025-05-11 | 1.97 |
| 2025-04-17 | 2025-04-30 | 1.97 |
| 2025-04-16 | 2025-04-16 | 1579.28 |
| 2025-03-18 | 2025-04-09 | 1.97 |
| 2025-02-18 | 2025-03-06 | 1.98 |
| 2025-01-16 | 2025-02-11 | 1.98 |
| 2025-01-02 | 2025-01-13 | 1.98 |
| 2024-12-22 | 2024-12-31 | 1.98 |
| 2024-12-17 | 2024-12-20 | 1.98 |
| 2024-07-16 | 2024-07-28 | 39.03 |
| 2024-02-20 | 2024-03-12 | 2.12 |
| 2024-02-19 | 2024-02-19 | 1273.60 |
| 2024-01-16 | 2024-02-18 | 1.80 |
| 2023-12-18 | 2024-01-09 | 1.80 |
| 2023-11-16 | 2023-12-10 | 1.80 |
| 2023-10-17 | 2023-11-12 | 1.80 |
| 2023-09-18 | 2023-10-09 | 1.80 |
| 2023-08-17 | 2023-09-12 | 1.80 |
| 2023-07-18 | 2023-07-25 | 0.78 |
| 2023-06-16 | 2023-07-11 | 0.78 |
| 2023-05-16 | 2023-06-14 | 0.78 |
| 2023-05-02 | 2023-05-14 | 0.78 |
| 2023-04-26 | 2023-04-28 | 0.78 |
| 2022-12-16 | 2022-12-28 | 4.42 |
| 2022-11-24 | 2022-12-06 | 4.42 |
| 2022-05-19 | 2022-05-26 | 5.90 |
| 2022-05-17 | 2022-05-18 | 970.10 |
| 2022-04-22 | 2022-05-16 | 5.90 |
| 2022-04-19 | 2022-04-21 | 890.18 |
| 2022-03-18 | 2022-04-18 | 5.90 |
| 2022-03-16 | 2022-03-17 | 866.43 |
| 2022-02-17 | 2022-02-17 | 877.40 |
MAVIRENA - VMI tax arrears
As of 2026-09-21, the amount of overdue STI tax debt of the company MAVIRENA is: 31 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-18 | 2026-09-21 | 31.09 |
| 2026-09-11 | 2026-09-17 | 35.56 |
| 2026-09-01 | 2026-09-10 | 31.09 |
| 2026-08-31 | 2026-08-31 | 19.09 |
| 2026-08-06 | 2026-08-30 | 14.29 |
| 2026-08-05 | 2026-08-05 | 4466.29 |
| 2026-07-01 | 2026-08-04 | 14.29 |
| 2026-06-03 | 2026-06-30 | 9.76 |
| 2026-06-01 | 2026-06-02 | 4505.82 |
| 2026-05-28 | 2026-05-31 | 4496.9 |
| 2026-05-19 | 2026-05-27 | 0.9 |
| 2026-05-17 | 2026-05-18 | 2.25 |
| 2026-05-06 | 2026-05-16 | 0.9 |
| 2026-05-01 | 2026-05-05 | 1171.34 |
| 2026-04-30 | 2026-04-30 | 1170.44 |
| 2026-04-01 | 2026-04-02 | 233.26 |
| 2026-03-29 | 2026-03-31 | 232.68 |
| 2026-03-02 | 2026-03-02 | 443.43 |
| 2026-02-27 | 2026-03-01 | 11.1 |
| 2026-02-21 | 2026-02-26 | 1222.0 |
| 2026-02-03 | 2026-02-16 | 5533.99 |
| 2026-01-31 | 2026-02-02 | 5517.69 |
| 2026-01-29 | 2026-01-30 | 5516.99 |
| 2026-01-22 | 2026-01-28 | 1325.99 |
| 2025-12-17 | 2026-01-21 | 3.99 |
| 2025-12-11 | 2025-12-16 | 4.22 |
| 2025-12-01 | 2025-12-10 | 3.99 |
| 2025-11-30 | 2025-11-30 | 0.63 |
| 2025-11-28 | 2025-11-29 | 4316.63 |
| 2025-11-02 | 2025-11-27 | 0.63 |
| 2025-08-07 | 2025-08-07 | 10.65 |
| 2025-08-01 | 2025-08-06 | 10.28 |
| 2025-07-02 | 2025-07-31 | 4.5 |
| 2025-07-01 | 2025-07-01 | 2609.5 |
| 2025-06-30 | 2025-06-30 | 1.0 |
| 2025-06-02 | 2025-06-29 | 1.06 |
| 2025-05-20 | 2025-05-28 | 1.12 |
| 2025-05-06 | 2025-05-19 | 295.1 |
| 2025-05-01 | 2025-05-05 | 1.3 |
| 2025-04-02 | 2025-04-30 | 1.26 |
| 2025-03-28 | 2025-04-01 | 159.0 |
| 2025-03-02 | 2025-03-27 | 2.8 |
| 2025-02-26 | 2025-03-01 | 2.4 |
| 2025-02-23 | 2025-02-25 | 1119.82 |
| 2025-02-20 | 2025-02-22 | 1118.62 |
| 2025-02-14 | 2025-02-19 | 8.62 |
| 2025-02-06 | 2025-02-13 | 8.84 |
| 2025-02-05 | 2025-02-05 | 8.36 |
| 2025-02-04 | 2025-02-04 | 1809.31 |
| 2025-02-02 | 2025-02-03 | 1807.87 |
| 2025-02-01 | 2025-02-01 | 1795.17 |
| 2025-01-31 | 2025-01-31 | 4664.1 |
| 2025-01-30 | 2025-01-30 | 4664.31 |
| 2025-01-29 | 2025-01-29 | 2890.31 |
| 2025-01-19 | 2025-01-28 | 2901.31 |
| 2025-01-08 | 2025-01-18 | 2884.93 |
| 2024-12-31 | 2025-01-07 | 8.93 |
| 2024-12-03 | 2024-12-30 | 7.74 |
| 2024-11-30 | 2024-12-02 | 4421.16 |
| 2024-11-29 | 2024-11-29 | 3679.16 |
| 2024-10-29 | 2024-11-28 | 2.16 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MAVIRENA, UAB (code 300640302) is a Private Limited Liability Company operating in freight transport by road. In 2025, the company generated revenue of €433.4K, up 12.3% year on year and 48.3% over two years, but it remained loss-making with a net loss of €26.7K and a profit margin of -6.2%. The three-year trend shows steadily rising turnover from €292.3K in 2023 to €385.9K in 2024 and €433.4K in 2025, while net losses deepened from €20.8K to €21.6K and then to €26.7K. The 2025 balance sheet shows total assets of €126.3K, liabilities of €138.2K and negative equity of €11.9K, compared with assets of €193.6K and equity of €14.8K in 2024. Asset turnover stood at 3.43x, and return on assets was -21.1%. Return on equity is distorted by negative equity and should be interpreted cautiously. Revenue per employee was €61.9K, while profit per employee was -€3.8K, indicating positive sales growth but continued pressure on profitability and capital structure.